Cardiovascular outcomes of antidiabetic drugs

Authors

  • Ranjit Kumar Nath Professor and Head, Department of Cardiology, Dr Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India https://orcid.org/0000-0002-8258-0445
  • Neeraj Pandit Professor, Department of Cardiology, Dr Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India
  • Ajay Raj Professor, Department of Cardiology, Dr Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India
  • B.N Pandit Associate Professor, Department of Cardiology, Dr Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India
  • Vinod Kumar Senior Resident, Department of Cardiology, Dr Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India https://orcid.org/0000-0002-1001-2684
  • Rajeev Bhardwaj Senior Resident, Department of Cardiology, Dr Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India
  • Ajay Pratap Singh Senior Resident, Department of Cardiology, Dr Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India https://orcid.org/0000-0003-3127-6539
  • Ashok Thakur Senior Resident, Department of Cardiology, Dr Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India https://orcid.org/0000-0001-6502-5717

DOI:

https://doi.org/10.3126/ajms.v12i3.32477

Keywords:

Antidiabetic drugs, Cardiovascular outcomes, DPP 4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonist

Abstract

Type 2 Diabetes Mellitus (T2DM) is associated with a high risk of atherosclerotic cardiovascular disease (ASCVD). Intensive blood glucose reduction with antidiabetic drugs significantly reduce microvascular complications but there is no strong evidence of reduction in cardiovascular (CV) events. In 2008, the US Food and Drug Administration (FDA) issued guidance to demonstrate cardiovascular safety of newer antidiabetic drugs in addition to reduction in blood glucose level. After which a number of CVOTs were conducted involving newer antidiabetic drugs. The newer drugs (e.g. GLP-1 RAs, SGLT2 inhibitors and DPP 4 inhibitors) might have potential effects on body weight, lipid parameters and blood pressure, as well as endothelial dysfunctions, inflammatory markers and oxidative stress. The current review summarizes the results of the main trials focused on the cardiovascular outcomes of traditional as well as newer antidiabetic drugs.

Downloads

Download data is not yet available.
Abstract
272
PDF
278

Downloads

Published

2021-03-01

How to Cite

Nath, R. K., Pandit, N., Raj, A., Pandit, B., Kumar, V., Bhardwaj, R., Singh, A. P., & Thakur, A. (2021). Cardiovascular outcomes of antidiabetic drugs. Asian Journal of Medical Sciences, 12(3), 98–106. https://doi.org/10.3126/ajms.v12i3.32477

Issue

Vol. 12 No. 3 (2021)

Section

Review Articles

License

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).